ArticleInternational journal of nanomedicine2014
Evaluating the potential of cubosomal nanoparticles for oral delivery of amphotericin B in treating fungal infection.
Article in International journal of nanomedicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 75 citations in OpenAlex.
- Lipid-Based Drug Delivery Systems as Emerging Tools to Overcome Antifungal Resistance.International journal of molecular sciences · 2026Review
- Oral Drug Delivery via Intestinal Lymphatic Transport Utilizing Lipid-Based Lyotropic Liquid Crystals.Liquids · 2023Article
- Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application.Drug delivery · 2023Review
- Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems.Pharmaceutics · 2023Review
- Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations.Pharmaceutics · 2022Review
- Orally Administered Amphotericin B Nanoformulations: Physical Properties of Nanoparticle Carriers on Bioavailability and Clinical Relevance.Pharmaceutics · 2022Review
- Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Lipid Cubic Systems for Sustained and Controlled Delivery of Antihistamine Drugs.Molecular pharmaceutics · 2021Article
- Recent advances in drug delivery applications of cubosomes, hexosomes, and solid lipid nanoparticles.Acta pharmaceutica Sinica. B · 2021Review
- Liquid Crystalline Phases for Enhancement of Oral Bioavailability.AAPS PharmSciTech · 2021Review
- Current applications and prospects of nanoparticles for antifungal drug delivery.EXCLI journal · 2021Review
- Strategies to enhance oral delivery of amphotericin B: a comparison of uncoated and enteric-coated nanostructured lipid carriers.Drug delivery · 2020Article
- Investigation of thiosemicarbazide free or within chitosan nanoparticles in a murine model of vulvovaginal candidiasis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2020Article
- The use of nanoparticles as alternative therapeutic agents against Candida infections: an up-to-date overview and future perspectives.World journal of microbiology & biotechnology · 2020Review
- Copolymeric Micelles Overcome the Oral Delivery Challenges of Amphotericin B.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy.Pharmaceutics · 2020Review
- Cubosomes: The Next Generation of Smart Lipid Nanoparticles?Angewandte Chemie (International ed. in English) · 2019Review
- Recent insights on nanomedicine for augmented infection control.International journal of nanomedicine · 2019Review
- Role of nanostructures in improvising oral medicine.Toxicology reports · 2019Review
- RETRACTED: Preparation and Characterization of Spherical Amorphous Solid Dispersion with Amphotericin B.Pharmaceutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The oral administration of amphotericin B (AmB) has a major drawback of poor bioavailability. The aim of this study was to investigate the potential of glyceryl monoolein (GMO) cubosomes as lipid nanocarriers to improve the oral efficacy of AmB. Antifungal efficacy was determined in vivo in rats after oral administration, to investigate its therapeutic use. The human colon adenocarcinoma cell line (Caco-2) was used in vitro to evaluate transport across a model of the intestinal barrier. In vivo antifungal results showed that AmB, loaded in GMO cubosomes, could significantly enhance oral efficacy, compared against Fungizone, and that during a 2 day course of dosage 10 mg/kg the drug reached effective therapeutic concentrations in renal tissue for treating fungal infections. In the Caco-2 transport studies, GMO cubosomes resulted in a significantly larger amount of AmB being transported into Caco-2 cells, via both clathrin- and caveolae-mediated endocytosis, but not macropinocytosis. These results suggest that GMO cubosomes, as lipid nanovectors, could facilitate the oral delivery of AmB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.